186 related articles for article (PubMed ID: 27339229)
1. Competitive inhibition of TRPV1-calmodulin interaction by vanilloids.
Hetényi A; Németh L; Wéber E; Szakonyi G; Winter Z; Jósvay K; Bartus É; Oláh Z; Martinek TA
FEBS Lett; 2016 Aug; 590(16):2768-75. PubMed ID: 27339229
[TBL] [Abstract][Full Text] [Related]
2. Activation of endogenous TRPV1 fails to induce overstimulation-based cytotoxicity in breast and prostate cancer cells but not in pain-sensing neurons.
Pecze L; Jósvay K; Blum W; Petrovics G; Vizler C; Oláh Z; Schwaller B
Biochim Biophys Acta; 2016 Aug; 1863(8):2054-64. PubMed ID: 27180305
[TBL] [Abstract][Full Text] [Related]
3. Rational design and validation of a vanilloid-sensitive TRPV2 ion channel.
Yang F; Vu S; Yarov-Yarovoy V; Zheng J
Proc Natl Acad Sci U S A; 2016 Jun; 113(26):E3657-66. PubMed ID: 27298359
[TBL] [Abstract][Full Text] [Related]
4. Anti-calmodulins and tricyclic adjuvants in pain therapy block the TRPV1 channel.
Oláh Z; Jósvay K; Pecze L; Letoha T; Babai N; Budai D; Otvös F; Szalma S; Vizler C
PLoS One; 2007 Jun; 2(6):e545. PubMed ID: 17579717
[TBL] [Abstract][Full Text] [Related]
5. Understanding TRPV1 activation by ligands: Insights from the binding modes of capsaicin and resiniferatoxin.
Elokely K; Velisetty P; Delemotte L; Palovcak E; Klein ML; Rohacs T; Carnevale V
Proc Natl Acad Sci U S A; 2016 Jan; 113(2):E137-45. PubMed ID: 26719417
[TBL] [Abstract][Full Text] [Related]
6. Pain-enhancing mechanism through interaction between TRPV1 and anoctamin 1 in sensory neurons.
Takayama Y; Uta D; Furue H; Tominaga M
Proc Natl Acad Sci U S A; 2015 Apr; 112(16):5213-8. PubMed ID: 25848051
[TBL] [Abstract][Full Text] [Related]
7. Ca(2+) binding protein S100A1 competes with calmodulin and PIP2 for binding site on the C-terminus of the TPRV1 receptor.
Grycova L; Holendova B; Lansky Z; Bumba L; Jirku M; Bousova K; Teisinger J
ACS Chem Neurosci; 2015 Mar; 6(3):386-92. PubMed ID: 25543978
[TBL] [Abstract][Full Text] [Related]
8. Distinct properties of Ca2+-calmodulin binding to N- and C-terminal regulatory regions of the TRPV1 channel.
Lau SY; Procko E; Gaudet R
J Gen Physiol; 2012 Nov; 140(5):541-55. PubMed ID: 23109716
[TBL] [Abstract][Full Text] [Related]
9. Pungency of TRPV1 agonists is directly correlated with kinetics of receptor activation and lipophilicity.
Ursu D; Knopp K; Beattie RE; Liu B; Sher E
Eur J Pharmacol; 2010 Sep; 641(2-3):114-22. PubMed ID: 20576527
[TBL] [Abstract][Full Text] [Related]
10. Human keratinocytes are vanilloid resistant.
Pecze L; Szabó K; Széll M; Jósvay K; Kaszás K; Kúsz E; Letoha T; Prorok J; Koncz I; Tóth A; Kemény L; Vizler C; Oláh Z
PLoS One; 2008; 3(10):e3419. PubMed ID: 18852901
[TBL] [Abstract][Full Text] [Related]
11. Vanilloid receptor agonists and antagonists are mitochondrial inhibitors: how vanilloids cause non-vanilloid receptor mediated cell death.
Athanasiou A; Smith PA; Vakilpour S; Kumaran NM; Turner AE; Bagiokou D; Layfield R; Ray DE; Westwell AD; Alexander SP; Kendall DA; Lobo DN; Watson SA; Lophatanon A; Muir KA; Guo DA; Bates TE
Biochem Biophys Res Commun; 2007 Mar; 354(1):50-5. PubMed ID: 17214968
[TBL] [Abstract][Full Text] [Related]
12. TRPV1 channels and the progesterone receptor Sig-1R interact to regulate pain.
Ortíz-Rentería M; Juárez-Contreras R; González-Ramírez R; Islas LD; Sierra-Ramírez F; Llorente I; Simon SA; Hiriart M; Rosenbaum T; Morales-Lázaro SL
Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1657-E1666. PubMed ID: 29378958
[TBL] [Abstract][Full Text] [Related]
13. Antinociceptive desensitizing actions of TRPV1 receptor agonists capsaicin, resiniferatoxin and N-oleoyldopamine as measured by determination of the noxious heat and cold thresholds in the rat.
Bölcskei K; Tékus V; Dézsi L; Szolcsányi J; Petho G
Eur J Pain; 2010 May; 14(5):480-6. PubMed ID: 19800272
[TBL] [Abstract][Full Text] [Related]
14. Resiniferatoxin mediated ablation of TRPV1+ neurons removes TRPA1 as well.
Pecze L; Pelsoczi P; Kecskés M; Winter Z; Papp A; Kaszás K; Letoha T; Vizler C; Oláh Z
Can J Neurol Sci; 2009 Mar; 36(2):234-41. PubMed ID: 19378721
[TBL] [Abstract][Full Text] [Related]
15. Targeting TRPV1 for pain relief: limits, losers and laurels.
Szallasi A; Sheta M
Expert Opin Investig Drugs; 2012 Sep; 21(9):1351-69. PubMed ID: 22780443
[TBL] [Abstract][Full Text] [Related]
16. TRPV1, NK1 receptor and substance P immunoreactivity and gene expression in the rat lumbosacral spinal cord and urinary bladder after systemic, low dose vanilloid administration.
Heng YJ; Saunders CI; Kunde DA; Geraghty DP
Regul Pept; 2011 Apr; 167(2-3):250-8. PubMed ID: 21329730
[TBL] [Abstract][Full Text] [Related]
17. Involvement of capsaicin-sensitive afferents and the Transient Receptor Potential Vanilloid 1 Receptor in xylene-induced nocifensive behaviour and inflammation in the mouse.
Sándor K; Helyes Z; Elekes K; Szolcsányi J
Neurosci Lett; 2009 Feb; 451(3):204-7. PubMed ID: 19159661
[TBL] [Abstract][Full Text] [Related]
18. Engineering vanilloid-sensitivity into the rat TRPV2 channel.
Zhang F; Hanson SM; Jara-Oseguera A; Krepkiy D; Bae C; Pearce LV; Blumberg PM; Newstead S; Swartz KJ
Elife; 2016 May; 5():. PubMed ID: 27177419
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting of TRPV1 by resiniferatoxin, from preclinical studies to clinical trials.
Kissin I; Szallasi A
Curr Top Med Chem; 2011; 11(17):2159-70. PubMed ID: 21671878
[TBL] [Abstract][Full Text] [Related]
20. Detailed Analysis of the Binding Mode of Vanilloids to Transient Receptor Potential Vanilloid Type I (TRPV1) by a Mutational and Computational Study.
Ohbuchi K; Mori Y; Ogawa K; Warabi E; Yamamoto M; Hirokawa T
PLoS One; 2016; 11(9):e0162543. PubMed ID: 27606946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
